TomoTherapy — Merger or Acquisition (March 2011)
22 slides from TomoTherapy's merger presentation, Mar 8, 2011
Slide 1: Creating the Premier Radiation Oncology Company
Creating the Premier Radiation Oncology Company
Slide 2: Forward-looking Statement Safe Harbor Statement
Forward-looking Statement Safe Harbor Statement The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry and the transaction between Accuray and TomoTherapy. Except for the historical inform
Slide 3: Agenda
Agenda Welcome Tom RathjenDeal Summary Euan ThomsonCorporate and Product Overview Accuray Overview (Euan Thomson)TomoTherapy Overview (Fred Robertson)Financial Profile Derek BertocciExecutive Summary Euan Thomson Q&A All
Slide 4: Strategic Rationale
Strategic Rationale Complementary patient populations, treated by the same medical specialtySignificant increase in global presenceFinancial benefits anticipated from operating efficiencies and G&A synergies Combining two best-in-class technologies to create the premier radiation oncology company
Slide 5: Deal Summary
Deal Summary
Slide 6: Deal Terms
Deal Terms TomoTherapy shareholders to receive $4.80 per share* in cash and stock $3.15 in cash0.1648 shares of Accuray stock ($1.65)Expected to be accretive to Accuray's EPS in its fiscal year beginning July 1, 2012Approved by both companies' Board of DirectorsAnticipated to close in Q2 or early Q3
Slide 7: Corporate and Product Overview
Corporate and Product Overview
Slide 8: Accuray Incorporated
Accuray Incorporated Accuray Incorporated 200+ systems installed 100,000+ patients treated 75+ issued patents *as of December 31, 2010
Slide 9: Accuray Record of Achievement
Accuray Record of Achievement Consistent record of technology innovationRegular upgrades support premium service programsNew CyberKnife(r) platforms support stronger pricingProven ability to drive market acceptanceNew productsNew clinical capabilitiesProfitabilityProduct gross profit margin (>60% in
Slide 10: TomoTherapy Incorporated
TomoTherapy Incorporated Data provided by TomoTherapy Headquarters Madison, WI International Office Brussels NASDAQ Ticker: TOMO Employees 636* Revenue (FY2010) $195M Guidance (FY2011) $215-$235M Product Backlog $133M* 350 systems** 110,000+ patients treated 130+ issued patents **Shipped and/or inst
Slide 11: TomoTherapy Corporate and Product Strategy
TomoTherapy Corporate and Product Strategy r TOMOTHERAPY(r) PLATFORMDaily CT guidance capabilitiesUnique helical delivery of IMRT Highly conformal dose distributions for simple and complex target volumesEnhanced platform versatility with TomoDirect(tm), TomoHD(tm) and TomoMobile(tm) TOMOTHERAPY INCO
Slide 12: Financial Profile
Financial Profile
Slide 13: Keys to Financial Success of Acquisition
Keys to Financial Success of Acquisition Product Revenue: Maintain / GrowBest in class IMRT technologyProfitable product revenueContinue growth in orders and revenue seen in CY 2010Service: Turn From Loss to ProfitImprove product reliabilityReduce cost of serviceCost Synergies: Reduce Operating Expe
Slide 14: Product Revenue
Product Revenue Customer RelationshipsSignificantly larger sales forceEnhanced and more frequent customer contactsGreater Global PresenceDirect service opportunitiesDirect sales opportunities in select countriesLarger product portfolioMore opportunities for customer contactR&D (future product initia
Slide 15: Service Actions to Turn Profitable
Service Actions to Turn Profitable Fast Track Program (quarter ended December 31, 2010)Upgrade specific systems with high service costsTomoTherapy Plan: Design, Serviceability, TrainingDesign changes to enhance reliability and serviceabilityRevise procedures and training in manufacturing and service
Slide 16: Cost Synergies
Cost Synergies Examples Reduced G&A ExpensesPublic Company "overhead"e.g. Audit fees, SEC filings Corporate management duplicationMarketing ExpenseTrade show attendanceProfessional membership feesUsers' eventsExpected Gross Operating Expense Synergies Approximately $25M per year by year two
Slide 17: Summary Corporate Metrics
Summary Corporate Metrics Metric Accuray TomoTherapy Revenue (CY2010) $206.1M $195.4M Net Income (CY2010) $6.8M ($29.9M) Expected Gross Operational Synergies Approx. $25M per year Approx. $25M per year Product Backlog (Dec. 31, 2010) $170M* $133M** Installed Base 222 (12/31/10) 350*** (2/17/11) *Bas
Slide 18: Executive Summary
Executive Summary
Slide 19: Increased Global Presence
Increased Global Presence Worldwide Install Base (CHART) (CHART) 572 Systems Installed** Worldwide Accuray TomoTherapy Americas EIMEA Japan APAC (CHART) Accuray Post Transaction 222 Systems Installed* 350 Systems Installed** *Installed as of December 31, 2010**Shipped and/or installed as of February
Slide 20: Strategic Rationale
Strategic Rationale Complementary patient populations, treated by the same medical specialtySignificant increase in global presenceFinancial benefits anticipated from operating efficiencies and G&A synergies Combining two best-in-class technologies to create the premier radiation oncology company
Slide 21: Q&A
Q&A
Slide 22: Creating the Premier Radiation Oncology Company
Creating the Premier Radiation Oncology Company 3 3 4 5 6 **** Accuray Acquisition of TomoTherapy Key Messages 1 • Combining two best-in-class technologies to create the premier radiation oncology company Safe Harbor Statement The foregoing may contain certain forward-looking statements that involve